MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/pharmacy14030063

Медицинская библиотека · Pharmacy (Basel, Switzerland) · 2026

Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).

Llamas-Velasco Mar, Hospital Mercedes, López-Ferrer Anna, Herranz Pedro, Ruíz-Villaverde Ricardo, Mateu Almudena, García-Latasa Francisco Javier, Rivera Raquel, Fernández-Freire Lourdes Rodriguez, Alcazar Elena Del, Santos Sergio, Arias Salvador, Gónzalez-Cantero Alvaro, Belinchon Isabel, Carretero Gregorio, Ferran Marta, Ruiz-Genao Diana, Eiris Noemí, Sahuquillo Antonio, Mataix Javier, Carrascosa Jose-María, Cueva Pablo de la, Salgado-Boquete Laura

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations.

METHODS

We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis.

RESULTS

The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI < 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI < 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged ≥65 years, confirming the drug's utility in the elderly. Safety was consistent with previous reports, with no new signals detected.

CONCLUSIONS

Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.

Для цитирования: Llamas-Velasco Mar, Hospital Mercedes, López-Ferrer Anna, Herranz Pedro, Ruíz-Villaverde Ricardo, Mateu Almudena, García-Latasa Francisco Javier, Rivera Raquel, Fernández-Freire Lourdes Rodriguez, Alcazar Elena Del, Santos Sergio, Arias Salvador, Gónzalez-Cantero Alvaro, Belinchon Isabel, Carretero Gregorio, Ferran Marta, Ruiz-Genao Diana, Eiris Noemí, Sahuquillo Antonio, Mataix Javier, Carrascosa Jose-María, Cueva Pablo de la, Salgado-Boquete Laura. Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).. Pharmacy (Basel, Switzerland). 2026. DOI: 10.3390/pharmacy14030063.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.